Increased Patient Cost-Sharing, Weak US Economy, and Poor Health Habits: Implications for Employers and Insurers
In the spring of 2008, the Zitter Group conducted a large national study of the insurer–employer relationship to understand how these 2 stakeholders interact in the creation of healthcare benefit design. The 2-arm study consisted of concurrent web-based quantitative surveys with commercial managed care executives, large employers, and major employer benefits consultants.1 It was designed to provide a richly detailed snapshot of trends in employer-sponsored healthcare coverage.
The Cost-Sharing Conundrum: Greater Stakeholder Collaboration Needed
Obesity is associated with many chronic diseases and is classified as a disease by several organizations, including the World Health Organization, the National Institutes of Health, the US Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC).1-4
Payers' Incentives Are Not Aligned to Address the Obesity Epidemic
Health Insurance Premium Increases for the 5 Largest School Districts in the United States, 2004-2008
Local school districts are one of the largest employers in the United States, employing roughly 8 million employees in 2008.1 Locally, they are often one of the largest (if not the largest) employers in the communities they serve. Like many large employers, school districts offer an array of benefits to their employees, including health insurance. Employee benefits comprise 34.3% of total compensation for publicsector employees,2 with health insurance representing 10.9% of total compensation.2
Public Employer Characteristics
Health Insurance Premium Increases for Large Employers
As the number of patients with diabetes increases, there is growing concern about the adequacy of reimbursement levels for delivering comprehensive diabetes care.
Diabetes Management Strategies: More Money Does Not Equal Better Care
Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population
Maureen Kubacki, PharmD, MBA , Chureen Carter, PharmD, MS , Alan D. L. Herrera, PharmD, Jim Wang, PhD, Janice M.S. Lopez, PharmD, MPH, Catherine T. Piech, MBA
Chronic kidney disease (CKD) affects approximately 26 million people in the United States.1 Diabetes and hypertension cause up to two thirds of all new CKD cases.1,2 According to Medicare policy, health plans are financially responsible for the care of CKD patients for up to 33 months after they have reached the final stage of end-stage renal disease (ESRD).3 Data from the Institute for Health and Productivity Management 2001 database show that treatment costs nearly double from one stage of CKD to the next.4 The stages of CKD are defined based on
Alignment of Incentives along the Healthcare Payer Continuum for Patients with Kidney Disease
Impact of Prescription Benefit Coverage Limits on Sevelamer Hydrochloride Adherence for Patients with ESRD
Hyperphosphatemia is prevalent among patients with end-stage renal disease (ESRD) and continues to be an important and challenging area for drug therapy.
Balancing Horizontal and Vertical Equity within Managed Health Plans Drug Benefit
Nancy M. McGee, JD, MPH, Gene Reeder, RPh, PhD, Timothy S. Regan, BPharm, RPh, CPh, J.D. Kleinke, Steve Arnold, MD, MS, MBA, CPE
Across socioeconomic strata, American households are adopting an increasingly electronic way of life. Bills are routinely paid online, bank balances are tracked, goods are purchased, and music is downloaded at record consumer adoption rates.1 Income levels, bank balances, and consumer preferences are routinely shared and stored in the electronic ether. There is a unity of confidence and comfort on behalf of the consumer and the vendor that these personal pieces of information are safe and secure.
Electronic PHRs and e-Prescribing: Not Quite There Yet
Pharmaceutical manufacturers face an increasing drug utilization dilemma—not related to formulary acceptance—in the US marketplace regarding patent expiration, new-entry pharmaceuticals, and biotechnology products. Influencers of health plan reimbursement program decision makers (eg, benefit managers, consultants, consumer advocates) and reimbursement transaction platforms need more attention from pharmaceutical marketers and senior executives in relation to their current and emerging product pipeline.
The Many Challenges of Pay-for-Performance Programs
Impact of Etanercept Treatment on Absenteeism and Productivity: The Work Loss and Productivity Survey
Denise Globe, PhD, Peter Mazonson, MD, MBA, Chris Santas, MBA, Regina Murphy, MBA, Annie Cheng, Xingyue Huang, BPharm, PhD, Arthur Kavanaugh, MD
Rheumatoid arthritis (RA) is a chronic, disabling autoimmune disorder that affects approximately 1% of American adults.1 There has been substantial progress in our understanding of RA disease progression and in the development of therapies for its treatment in recent years.
What Is the Value of Specialty Pharmaceuticals?
Page 11 of 11
Results 101 - 109 of 109
Results 101 - 109 of 109